Limits...
A Recombinant Raccoon Poxvirus Vaccine Expressing both Yersinia pestis F1 and Truncated V Antigens Protects Animals against Lethal Plague.

Rocke TE, Kingstad-Bakke B, Berlier W, Osorio JE - Vaccines (Basel) (2014)

Bottom Line: In previous studies, we demonstrated in mice and prairie dogs that simultaneous administration of two recombinant raccoon poxviruses (rRCN) expressing Yersinia pestis antigens (F1 and V307-a truncated version of the V protein) provided superior protection against plague challenge compared to individual single antigen constructs.Here we report the construction and characterization of a novel RCN-vectored vaccine that simultaneously expresses both F1 and V307 antigens.The equivalent safety, immunogenicity and efficacy profile of the dual RCN-F1/V307 construct warrants further evaluation in field efficacy studies in sylvatic plague endemic areas.

View Article: PubMed Central - PubMed

Affiliation: National Wildlife Health Center, U.S. Geological Survey, 6006 Schroeder Rd., Madison, WI 53711, USA. trocke@usgs.gov.

ABSTRACT
In previous studies, we demonstrated in mice and prairie dogs that simultaneous administration of two recombinant raccoon poxviruses (rRCN) expressing Yersinia pestis antigens (F1 and V307-a truncated version of the V protein) provided superior protection against plague challenge compared to individual single antigen constructs. To reduce costs of vaccine production and facilitate implementation of a sylvatic plague vaccine (SPV) control program for prairie dogs, a dual antigen construct is more desirable. Here we report the construction and characterization of a novel RCN-vectored vaccine that simultaneously expresses both F1 and V307 antigens. This dual antigen vaccine provided similar levels of protection against plague in both mice and prairie dogs as compared to simultaneous administration of the two single antigen constructs and was also shown to protect mice against an F1 negative strain of Y. pestis. The equivalent safety, immunogenicity and efficacy profile of the dual RCN-F1/V307 construct warrants further evaluation in field efficacy studies in sylvatic plague endemic areas.

No MeSH data available.


Related in: MedlinePlus

Kaplan Meier survival curves for black-tailed prairie dog groups that consumed placebo or vaccine-laden baits. Group 1 consumed placebo baits containing RCN-TK- and was challenged at 30 or 270 days post initial vaccination (dpv). The other 3 groups consumed baits containing RCN-F1/V307. Groups 2 and 3 were challenged at 30 and 270 dpv, respectively. Group 4 consumed baits a second time 30 days prior to challenge at 270 dpv. Survival curves that do not share a letter are significantly different (p < 0.05).
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4494250&req=5

vaccines-02-00772-f003: Kaplan Meier survival curves for black-tailed prairie dog groups that consumed placebo or vaccine-laden baits. Group 1 consumed placebo baits containing RCN-TK- and was challenged at 30 or 270 days post initial vaccination (dpv). The other 3 groups consumed baits containing RCN-F1/V307. Groups 2 and 3 were challenged at 30 and 270 dpv, respectively. Group 4 consumed baits a second time 30 days prior to challenge at 270 dpv. Survival curves that do not share a letter are significantly different (p < 0.05).

Mentions: Survival rates were compared between all groups of PDs using Kaplan Meier survival analysis (Figure 3). As expected the two PD groups that received the empty vector only (RCN-TK-) and were challenged at 30 or 270 dpv had the lowest survival rates from plague challenge (13% and 8% respectively). As these two groups (group 1a and 1b in Table 5) were not significantly different (p > 0.05), they were combined for all further analyses.


A Recombinant Raccoon Poxvirus Vaccine Expressing both Yersinia pestis F1 and Truncated V Antigens Protects Animals against Lethal Plague.

Rocke TE, Kingstad-Bakke B, Berlier W, Osorio JE - Vaccines (Basel) (2014)

Kaplan Meier survival curves for black-tailed prairie dog groups that consumed placebo or vaccine-laden baits. Group 1 consumed placebo baits containing RCN-TK- and was challenged at 30 or 270 days post initial vaccination (dpv). The other 3 groups consumed baits containing RCN-F1/V307. Groups 2 and 3 were challenged at 30 and 270 dpv, respectively. Group 4 consumed baits a second time 30 days prior to challenge at 270 dpv. Survival curves that do not share a letter are significantly different (p < 0.05).
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4494250&req=5

vaccines-02-00772-f003: Kaplan Meier survival curves for black-tailed prairie dog groups that consumed placebo or vaccine-laden baits. Group 1 consumed placebo baits containing RCN-TK- and was challenged at 30 or 270 days post initial vaccination (dpv). The other 3 groups consumed baits containing RCN-F1/V307. Groups 2 and 3 were challenged at 30 and 270 dpv, respectively. Group 4 consumed baits a second time 30 days prior to challenge at 270 dpv. Survival curves that do not share a letter are significantly different (p < 0.05).
Mentions: Survival rates were compared between all groups of PDs using Kaplan Meier survival analysis (Figure 3). As expected the two PD groups that received the empty vector only (RCN-TK-) and were challenged at 30 or 270 dpv had the lowest survival rates from plague challenge (13% and 8% respectively). As these two groups (group 1a and 1b in Table 5) were not significantly different (p > 0.05), they were combined for all further analyses.

Bottom Line: In previous studies, we demonstrated in mice and prairie dogs that simultaneous administration of two recombinant raccoon poxviruses (rRCN) expressing Yersinia pestis antigens (F1 and V307-a truncated version of the V protein) provided superior protection against plague challenge compared to individual single antigen constructs.Here we report the construction and characterization of a novel RCN-vectored vaccine that simultaneously expresses both F1 and V307 antigens.The equivalent safety, immunogenicity and efficacy profile of the dual RCN-F1/V307 construct warrants further evaluation in field efficacy studies in sylvatic plague endemic areas.

View Article: PubMed Central - PubMed

Affiliation: National Wildlife Health Center, U.S. Geological Survey, 6006 Schroeder Rd., Madison, WI 53711, USA. trocke@usgs.gov.

ABSTRACT
In previous studies, we demonstrated in mice and prairie dogs that simultaneous administration of two recombinant raccoon poxviruses (rRCN) expressing Yersinia pestis antigens (F1 and V307-a truncated version of the V protein) provided superior protection against plague challenge compared to individual single antigen constructs. To reduce costs of vaccine production and facilitate implementation of a sylvatic plague vaccine (SPV) control program for prairie dogs, a dual antigen construct is more desirable. Here we report the construction and characterization of a novel RCN-vectored vaccine that simultaneously expresses both F1 and V307 antigens. This dual antigen vaccine provided similar levels of protection against plague in both mice and prairie dogs as compared to simultaneous administration of the two single antigen constructs and was also shown to protect mice against an F1 negative strain of Y. pestis. The equivalent safety, immunogenicity and efficacy profile of the dual RCN-F1/V307 construct warrants further evaluation in field efficacy studies in sylvatic plague endemic areas.

No MeSH data available.


Related in: MedlinePlus